A$0.044 0.0 0.0%
Last Trade - 09/04/21
| Market Cap | £35.6m |
| Enterprise Value | £28.6m |
| Revenue | £29.1k |
| Position in Universe | 1050th / 1893 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.050 | 0.20 | 0.16 | 0.092 | 0.20 | 0.094 | 3.00 | +13.5% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 26, 1999 |
| Public Since | October 12, 2007 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 1,450,787,169 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Select House,SE 901 L 9 109 Pitt Street, SYDNEY, 2000, Australia |
| Web | http://actinogen.com.au/ |
| Phone | +61 2 89647401 |
| Contact | () |
| Auditors | Ernst & Young |
As of 09/04/21, shares in Actinogen Medical are trading at A$0.044, giving the company a market capitalisation of £35.6m. This share price information is delayed by 15 minutes.
Shares in Actinogen Medical are currently trading at A$0.044 and the price has moved by 0.124k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Actinogen Medical price has moved by 68.37% over the past year.
Of the analysts with advisory recommendations for Actinogen Medical, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Actinogen Medical is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Actinogen Medical is scheduled to issue upcoming financial results on the following dates:
Actinogen Medical does not currently pay a dividend.
Actinogen Medical does not currently pay a dividend.
Actinogen Medical does not currently pay a dividend.
To buy shares in Actinogen Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Actinogen Medical are currently trading at A$0.044, giving the company a market capitalisation of £35.6m.
Here are the trading details for Actinogen Medical:
Based on an overall assessment of its quality, value and momentum, Actinogen Medical is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Actinogen Medical.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actinogen Medical. Over the past six months, the relative strength of its shares against the market has been 45.44%. At the current price of A$0.044, shares in Actinogen Medical are trading at 81.87% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Actinogen Medical.
Actinogen Medical's management team is headed by:
Here are the top five shareholders of Actinogen Medical based on the size of their shareholding:
